Why the study?
Pulmonary epithelioid hemangioendothelioma is rare, often misdiagnosed due to non-specific clinical and radiological findings, and lacks an established standard treatment.
This review highlights the clinical characteristics, diagnostic challenges, and management strategies for pulmonary epithelioid hemangioendothelioma, emphasizing the need for standardized treatments and the potential of future targeted therapies.
P-EHE lacks standardized therapy; leaves open prospective trials of targeted agents in this rare neoplasm.
Epithelioid hemangioendothelioma (EHE) is a rare vascular neoplasm that develops from vascular endothelial cells. It has been reported to occur many sites of body, but the most common EHE presentations are soft tissue (limbs), bone, liver and lung. Compared with other pulmonary tumors, pulmonary epithelioid hemangioendothelioma (P-EHE) is relatively rare. According to a literature review, more than 100 cases have been described all over the world. Due to the low incidence of P-EHE, lack of specificity in clinical symptoms and radiological findings, it is often misdiagnosed. Meanwhile, many patients do not receive appropriate treatment, resulting in poor prognosis in some cases. Histology and immunohistochemical methods are essential for diagnosis. However, there is no established standard treatment for P-EHE, because of the rarity of the disease. When the lesions are small and limited in number, surgical is the best treatment, achieving the purpose of diagnosis and treatment at the same time. This article tries to present the etiopathogenesis, clinical manifestations, diagnosis, treatment and prognosis of P-EHE. .
No takes yet. Share an insight, caveat, or question.
Hang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: